Pamlectabart tismanitin

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NamePamlectabart tismanitin
Drug Alias NameHDP-101HDP101-ATACHDM2027
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Amanitin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionBacterial DNA-directed RNA polymerase inhibitorsAnti-BCMA
TargetsBacterial DNA-directed RNA polymeraseB-cell maturation protein
Therapy Area/IndicationsParaproteinemiasHematologic DiseasesMultiple Myeloma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandHungary +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHeidelberg Pharma AG
China Registration ClassN/A

Develop Information

Active CompaniesHuadong Medicine Co LtdCarbogen Amcis SASXERIMIS Inc +[5] 
Inactive CompaniesN/A
Active IndicationsParaproteinemiasHematologic DiseasesMultiple Myeloma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A